Quantinno Capital Management LP Sells 168,471 Shares of Perrigo Company plc $PRGO

Quantinno Capital Management LP trimmed its stake in Perrigo Company plc (NYSE:PRGO) by 25.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 493,866 shares of the company’s stock after selling 168,471 shares during the period. Quantinno Capital Management LP owned approximately 0.36% of Perrigo worth $5,304,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PRGO. Amundi lifted its position in Perrigo by 11.7% in the first quarter. Amundi now owns 5,292 shares of the company’s stock worth $148,000 after buying an additional 556 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Perrigo by 126.6% during the first quarter. Goldman Sachs Group Inc. now owns 1,159,768 shares of the company’s stock valued at $32,520,000 after acquiring an additional 647,982 shares during the last quarter. United Services Automobile Association bought a new position in Perrigo during the first quarter valued at $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Perrigo by 6.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,112 shares of the company’s stock valued at $14,388,000 after acquiring an additional 32,151 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Perrigo by 439.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock worth $27,000 after acquiring an additional 786 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company’s stock.

Perrigo Stock Performance

PRGO stock opened at $12.53 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 1.31. The business’s fifty day simple moving average is $10.58 and its two-hundred day simple moving average is $11.53. Perrigo Company plc has a twelve month low of $9.23 and a twelve month high of $24.60. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -1.00, a PEG ratio of 1.38 and a beta of 0.51.

Perrigo (NYSE:PRGO) last issued its earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.19. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. Perrigo had a negative net margin of 41.85% and a positive return on equity of 11.25%. The business’s revenue was down 3.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.06) earnings per share. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts predict that Perrigo Company plc will post 2.4 earnings per share for the current year.

Perrigo Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Friday, August 28th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.16 annualized dividend and a yield of 9.3%. Perrigo’s dividend payout ratio is -8.85%.

Key Stories Impacting Perrigo

Here are the key news stories impacting Perrigo this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.50, well above the $0.31 analyst consensus, while revenue of approximately $1.02 billion was in line with estimates. The company also returned to profitability compared with a loss in the prior-year quarter. Perrigo Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Infant Formula sales increased 23.1%, supported by contract-shipment timing and stronger store-brand formula demand, helping offset weaker performance in other categories. Perrigo Stock Rises as Q2 Earnings and Sales Beat Estimates
• Positive Sentiment: Perrigo reaffirmed its full-year 2026 outlook and provided EPS guidance of $2.25-$2.55, above the $2.11 consensus estimate. Management expects a stronger second half and cited market-share gains in U.S. store-brand over-the-counter products and key European brands. Perrigo Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: The company completed its Dermacosmetics divestiture and continues strategic reviews of its Infant Formula and Oral Care businesses, signaling portfolio streamlining but also uncertainty around future growth drivers.
• Negative Sentiment: Second-quarter net sales fell roughly 3.1%-3.2% year over year, core organic sales declined 3.5%, and management acknowledged softer category demand and macroeconomic headwinds. Total debt stood at approximately $3.3 billion versus $400 million of cash, which may keep investors cautious despite the earnings beat. Perrigo Q2 Net Sales Fall

Wall Street Analyst Weigh In

Several brokerages recently commented on PRGO. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $19.33.

Perrigo Company Profile

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.